Antithrombotic medications Apixaban G Dabigatran G Dabigatran etexilate IND Ravulizumab IND Rivaroxaban IND Cardiovascular diseases Macitentan IND Hemostasis promoting medication Eptacog beta (activated) Etranacogene dezaparvovec FLT180a Fibrinogen Fidanacogene elaparvovec Lipid-lowering medications Bempedoic acid Bempedoic acid / ezetimibe Evinacumab Evolocumab IND Inclisiran Other medication for cardiovascular diseases Allogenic immunomodulatory progenitor cells Apabetalon Dapagliflozine Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. IND Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). IND Emiplacel Empagliflozine Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). IND Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. IND Icosapent ethyl Omecamtiv mecarbil Rilonacept Tafamidis IND Ticagrelor Extension of indication to include, in co administration with acetylsalicylic acid (ASA), the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) without a history of myocardial infarction who have undergone percutaneous coronary intervention (PCI). IND Extension of indication to include, in co-administration with acetylsalicylic acid (ASA), the prevention of stroke in adult patients with acute ischaemic stroke or transient ischaemic attack (TIA) in the previous 24 hours. IND Udenafil Valsartan / sacubitril IND Vericiguat Other non-oncological hematological medications Avatrombopag Betibeglogene autotemcel Zynteglo is geïndiceerd voor gebruik bij patiënten in de leeftijd van 12 jaar en ouder met transfusie-afhankelijke β-thalassemie (transfusion-dependent β-thalassaemia - TDT) die geen β0/β0-genotype hebben, voor wie transplantatie van hematopoëtische stamcellen (HSC) gepast is, maar geen humaan leukocytenantigeen (HLA)-compatibele gerelateerde HSC-donor beschikbaar is. Behandeling van patiënten jonger dan 12 jaar met transfusie-afhankelijke β-thalassemie (TDT) die geen β0/β0-genotype hebben en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is. IND Behandeling van patiënten met transfusie-afhankelijke β-thalassemie (TDT) die een β0 mutatie op beide allelen van het β-globuline (HBB) hebben, en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is IND Crizanlizumab Daprodustat Deferasirox G Eculizumab Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). BS Efgartigimod Ferumoxytol Hydroxycarbamide IND Luspatercept IND Mepolizumab IND Mitapivat Pegcetacoplan RP-L102 Ravulizumab Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. Extension of indication to include treatment of paediatric patients with paroxysmal nocturnal haemoglobinuria (PNH) for Ultomiris. IND Romiplostim IND Roxadustat Thrombomodulin alfa Vadadustat Voxelotor